AN2 Therapeutics, Inc.
ANTX Nasdaq Pharmaceutical Preparations Financials FY2021–FY2025
Last close · Oct 23, 2026
$3.55
2.5%
Revenue
Total sales reported in the income statement.
—
vs prior year
Operating margin
Operating income as a share of revenue.
—
Net income
Profit after all expenses, interest and tax.
−$35.2M
Free cash flow
Cash from operations minus capital spending.
—
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
$159M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On −$1.07 EPS (TTM)
What AN2 Therapeutics, Inc. does
No business description yet.
- Legal name
- AN2 Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Accession · CIK
- 0001193125-26-110693
0001880438
Revenue and margins
AN2 Therapeutics, Inc. had — of revenue in fiscal 2025.
FY21
Revenue —
FY22
Revenue —
FY23
Revenue —
FY24
Revenue —
FY25
Revenue —
FY21
Gross —
Operating —
Net —
FCF —
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net —
FCF —
FY25
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY21
Net income −$21.5M
FY22
Net income −$41.0M
FY23
Net income −$64.7M
FY24
Net income −$51.3M
FY25
Net income −$35.2M
Q3 '23
Net income −$16.7M
Q4 '23
Net income −$16.9M
Q1 '24
Net income −$16.6M
Q2 '24
Net income −$14.4M
Q3 '24
Net income −$12.7M
Q4 '24
Net income −$7.5M
Q1 '25
Net income −$10.6M
Q2 '25
Net income −$6.5M
Q3 '25
Net income −$9.4M
Q4 '25
Net income −$8.7M
Q1 '26
Net income −$10.0M
Q2 '26
Net income −$8.2M
FY21
Diluted EPS −$10.64
FY22
Diluted EPS −$2.79
FY23
Diluted EPS −$2.74
FY24
Diluted EPS −$1.72
FY25
Diluted EPS −$1.16
Q3 '23
Diluted EPS −$0.65
Q4 '23
Diluted EPS −$0.49
Q1 '24
Diluted EPS −$0.56
Q2 '24
Diluted EPS −$0.48
Q3 '24
Diluted EPS −$0.43
Q4 '24
Diluted EPS −$0.25
Q1 '25
Diluted EPS −$0.35
Q2 '25
Diluted EPS −$0.21
Q3 '25
Diluted EPS −$0.31
Q4 '25
Diluted EPS −$0.29
Q1 '26
Diluted EPS −$0.29
Q2 '26
Diluted EPS −$0.18
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY21
Return on capital —
Return on equity —
Return on assets −33.0%
FY22
Return on capital —
Return on equity −170.8%
Return on assets −48.8%
FY23
Return on capital —
Return on equity −58.8%
Return on assets −53.7%
FY24
Return on capital —
Return on equity −49.7%
Return on assets −44.5%
FY25
Return on capital —
Return on equity −52.1%
Return on assets −45.7%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
FY21
Free cash flow —
FY22
Free cash flow —
FY23
Free cash flow —
FY24
Free cash flow —
FY25
Free cash flow —
FY21
Cash from operations −$20.5M
Capital spending —
FY22
Cash from operations −$33.5M
Capital spending —
FY23
Cash from operations −$53.3M
Capital spending —
FY24
Cash from operations −$49.3M
Capital spending —
FY25
Cash from operations −$29.8M
Capital spending —
Cash from operations
Capital spending
Q3 '23
Cash from operations −$11.8M
Capital spending —
Q4 '23
Cash from operations −$17.1M
Capital spending —
Q1 '24
Cash from operations −$17.6M
Capital spending —
Q2 '24
Cash from operations −$14.4M
Capital spending —
Q3 '24
Cash from operations −$12.0M
Capital spending —
Q4 '24
Cash from operations −$5.3M
Capital spending —
Q1 '25
Cash from operations −$10.6M
Capital spending —
Q2 '25
Cash from operations −$7.6M
Capital spending —
Q3 '25
Cash from operations −$6.4M
Capital spending —
Q4 '25
Cash from operations −$5.2M
Capital spending —
Q1 '26
Cash from operations −$12.1M
Capital spending —
Q2 '26
Cash from operations −$7.0M
Capital spending —
Cash from operations
Capital spending
Dividends, buybacks and share count
AN2 Therapeutics, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 1.3%.
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.02B
FY23
Diluted shares 0.02B
FY24
Diluted shares 0.03B
FY25
Diluted shares 0.03B
Balance sheet
Cash, debt and the ratios that show how comfortably AN2 Therapeutics, Inc. can carry it.
FY21
Cash $58.6M
Debt —
FY22
Cash $96.1M
Debt —
FY23
Cash $107M
Debt —
FY24
Cash $83.6M
Debt —
FY25
Cash $58.0M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $58.6M | $96.1M | $107M | $83.6M | $58.0M |
| Current ratio | 17.7x | 13.7x | 7.9x | 8.4x | 6.9x |
| Quick ratio | 17.7x | 13.7x | 7.9x | 8.4x | 6.9x |
| Total assets | $65.3M | $103M | $139M | $92.1M | $62.0M |
| Total liabilities | $3.4M | $7.2M | $14.0M | $10.2M | $8.9M |
| Shareholders' equity | −$47.4M | $95.4M | $125M | $81.8M | $53.1M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✕ | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — | — |
| Current ratio rose | — | ✕ | ✕ | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 | — / 6 | — / 6 |
| Accruals ratio | −1.6% | −8.9% | −9.5% | −1.8% | −6.9% |
| Altman Z'' | −13.50 | 14.16 | 6.88 | 2.38 | −5.12 |
5 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Research and development | $16.2M | $28.5M | $54.9M | $40.5M | $24.8M |
| Operating income | −$21.6M | −$42.3M | −$69.6M | −$56.8M | −$38.1M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$21.5M | −$41.0M | −$64.7M | −$51.3M | −$35.2M |
| Net income to common | −$28.1M | −$42.8M | −$64.7M | −$51.3M | −$35.2M |
| Diluted EPS | −$10.64 | −$2.79 | −$2.74 | −$1.72 | −$1.16 |
| Diluted shares | 0.00B | 0.02B | 0.02B | 0.03B | 0.03B |
| Cash flow | |||||
| Cash from operations | −$20.5M | −$33.5M | −$53.3M | −$49.3M | −$29.8M |
| Stock-based compensation | $1.0M | $4.4M | $8.4M | $8.3M | $6.2M |
| Balance sheet | |||||
| Cash and short-term investments | $58.6M | $96.1M | $107M | $83.6M | $58.0M |
| Current assets | $60.1M | $98.6M | $111M | $86.3M | $59.9M |
| Current liabilities | $3.4M | $7.2M | $14.0M | $10.2M | $8.7M |
| Total assets | $65.3M | $103M | $139M | $92.1M | $62.0M |
| Total liabilities | $3.4M | $7.2M | $14.0M | $10.2M | $8.9M |
| Shareholders' equity | −$47.4M | $95.4M | $125M | $81.8M | $53.1M |
| Returns | |||||
| Return on capital employed | −34.8% | −44.3% | −55.8% | −69.4% | −71.6% |
| Return on equity | — | −170.8% | −58.8% | −49.7% | −52.1% |
| Return on assets | −33.0% | −48.8% | −53.7% | −44.5% | −45.7% |
| Return on tangible equity | — | −44.9% | −51.9% | −62.7% | −66.3% |
| Growth | |||||
| Share count change | — | 481.5% | 53.8% | 26.4% | 1.3% |
| Financial health | |||||
| Current ratio | 17.7x | 13.7x | 7.9x | 8.4x | 6.9x |
| Quick ratio | 17.7x | 13.7x | 7.9x | 8.4x | 6.9x |
| Quality scores | |||||
| Altman Z'' | −13.5 | 14.2 | 6.9 | 2.4 | −5.1 |
| Accruals ratio | −1.6% | −8.9% | −9.5% | −1.8% | −6.9% |
Source: SEC EDGAR XBRL filings (CIK 0001880438). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.